glp-1 new drug Decoding Weight Loss Medications GLP-1 Drug Pipeline 2026 |

has served on scientific advisory panels and/or speaker's bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma

Although its anti-inflammatory properties may contribute to OSAS improvement, the complexity of immune regulation raises the possibility of unforeseen immune-related effects

Both compounds have long half-lives that maintain steady-state levels when dosed on a consistent schedule

A baby who still gets 80 percent of nutrition from breast milk has significant exposure

24 Based on these findings, two GLP-1 RAs were approved by the US FDA to treat obesity so far: liraglutide and semaglutide